What is Hexarelin?
Hexarelin is a synthetic six-residue growth-hormone secretagogue. The selected early human experiment measured hormone release, rather than muscle gain or injury recovery.
Biological role or research focus
Human endocrine physiology.
The study did not establish changes in strength, body composition, injury recovery, or long-term clinical outcomes. Twelve volunteers and an acute observation window cannot resolve sustained benefit or safety.
Role reference: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Names you may encounter
Examorelin · EP-23905
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic hexapeptide growth-hormone secretagogue
- Research focus
- Human endocrine physiology
- Featured evidence
- Human physiology study
- Source check
- October 4, 2026
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Quick answers
- Is Hexarelin FDA approved?
- No. No FDA-approved drug contains Hexarelin. Source ↗
- Is Hexarelin safe?
- Hexarelin is an unapproved growth-hormone secretagogue. Small human studies show it also raises cortisol, and its growth-hormone effect fades with ongoing use; long-term safety is unknown. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Hexarelin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Early healthy-volunteer physiology study (1994) | Human physiology study | 12 healthy adult men. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human physiology study · 1994
Early healthy-volunteer physiology study
Did hexarelin stimulate acute growth-hormone release?
- Population / model
- 12 healthy adult men.
- Study design
- Blinded placebo-controlled study examining acute hormone responses across studied exposures.
- Main finding
- Growth hormone rose after hexarelin, peaked at roughly 30 minutes, and returned toward baseline by about 240 minutes.
- Limits & context
- The study did not establish changes in strength, body composition, injury recovery, or long-term clinical outcomes. Twelve volunteers and an acute observation window cannot resolve sustained benefit or safety.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Hexarelin as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. ↗
International heart journal · 2017 Apr 6 · Journal Article
We are ageing. ↗
BioMed research international · 2014 · Journal Article, Review
Read available full text ↗
Growth hormone-releasing peptides. ↗
European journal of endocrinology · 1997 May · Journal Article, Research Support, Non-U.S. Gov't, Review
The cardiovascular action of hexarelin. ↗
Journal of geriatric cardiology : JGC · 2014 Sep · Journal Article, Review
Read available full text ↗
Risks & interactions
Hexarelin is an unapproved growth-hormone secretagogue. Small human studies show it also raises cortisol, and its growth-hormone effect fades with ongoing use; long-term safety is unknown.
Human data come from small studies, including one in adults over several months that tracked hormones and body composition. Longer-term safety and effects on other hormone pathways, such as cortisol, are not well characterized.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Growth hormone-releasing activity of hexarelin in humans (1994) ↗ · Hexarelin in patients with GH deficiency (1995) ↗ · Growth hormone status during long-term hexarelin therapy (1998) ↗ · Safety and efficacy of growth hormone secretagogues (review, 2018) ↗
What the featured evidence can tell us
An acute hormone-release study cannot establish safety during repeated exposure. Endocrine effects and possible effects on other hormone pathways need separate assessment.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Identity, route, and evidence limits
The study did not establish changes in strength, body composition, injury recovery, or long-term clinical outcomes. Twelve volunteers and an acute observation window cannot resolve sustained benefit or safety.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("examorelin (hexarelin)"). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
The evidence featured here is short-term experimental endocrine physiology. It does not establish a treatment for muscle growth, poor sleep, or tendon injuries.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
How Hexarelin works
Hexarelin stimulates growth-hormone release. In the selected study, the acute hormonal response was the measured outcome; it cannot be substituted for a demonstrated functional benefit.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Molecular structure
Questions worth asking
- Does a higher growth-hormone measurement prove more muscle?
- What population, comparator, and route were actually studied?
- The study did not establish changes in strength, body composition, injury recovery, or long-term clinical outcomes. Twelve volunteers and an acute observation window cannot resolve sustained benefit or safety.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does a higher growth-hormone measurement prove more muscle?
No. A hormone measurement is a surrogate outcome. Muscle strength, function, and adverse effects need direct measurement in an appropriate trial.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Growth hormone-releasing activity of hexarelin in humans. A dose-response study. · 1994 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
